Eli Lilly (LLY) shares fell almost 4% in recent trading Monday after the Trump administration decided to table a plan allowing Medicare to pay for anti-obesity medications, which would have granted more people access to the company's weight-loss drug Zepbound.
The Centers for Medicare & Medicaid Services said Friday it was not finalizing the provision in the proposed rule at this time, but may address it in the future.
A Lilly spokesperson said Medicare's decision was not the best interpretation of the Part D Coverage provision of the rule and will impacts the access to obesity treatment.
"We will continue to work with the Trump Administration and Congressional leaders to ensure people living with obesity are covered by Medicare and Medicaid and are no longer left behind," the spokesperson said.
Price: 709.32, Change: -28.89, Percent Change: -3.91
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。